Compass Pathways PLC banner

Compass Pathways PLC
NASDAQ:CMPS

Watchlist Manager
Compass Pathways PLC Logo
Compass Pathways PLC
NASDAQ:CMPS
Watchlist
Price: 6.31 USD -1.25% Market Closed
Market Cap: $605.9m

Compass Pathways PLC
Total Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Compass Pathways PLC
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Compass Pathways PLC
NASDAQ:CMPS
Total Current Assets
$201.3m
CAGR 3-Years
-12%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Total Current Assets
$536.4m
CAGR 3-Years
-5%
CAGR 5-Years
95%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Total Current Assets
£996.7m
CAGR 3-Years
37%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Total Current Assets
£303.9m
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
5%
Oxford BioMedica PLC
LSE:OXB
Total Current Assets
£131.8m
CAGR 3-Years
-13%
CAGR 5-Years
8%
CAGR 10-Years
17%
Niox Group PLC
LSE:NIOX
Total Current Assets
£22.4m
CAGR 3-Years
-2%
CAGR 5-Years
-11%
CAGR 10-Years
-22%
No Stocks Found

Compass Pathways PLC
Glance View

Market Cap
605.9m USD
Industry
Biotechnology

Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.

CMPS Intrinsic Value
0.71 USD
Overvaluation 89%
Intrinsic Value
Price

See Also

What is Compass Pathways PLC's Total Current Assets?
Total Current Assets
201.3m USD

Based on the financial report for Dec 31, 2024, Compass Pathways PLC's Total Current Assets amounts to 201.3m USD.

What is Compass Pathways PLC's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
44%

Over the last year, the Total Current Assets growth was -23%. The average annual Total Current Assets growth rates for Compass Pathways PLC have been -12% over the past three years , 44% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett